Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. Merck said the treatments when used as the initial treatment for advanced renal cell carcinoma (RCC) reduced the risk of death by about 47 percent in its late-stage trial. Keytruda has been Merck's most important growth driver with its domination of the lucrative lung cancer space, and shows no sign of slowing as it produces positive clinical data and adds approvals for different types of cancer.
Notes are encrypted so only you can see them.
How digital twins are transforming wind operations
Massachusetts DPU approves Vineyard Wind and utility contracts
Earth Day 2019 Activities–Be The Change to Protect the Species
Walmart and Sam’s Club’s “Fight Hunger. Spark Change.” Campaign Aims to
Open Space Increased Fleet Efficiency and Water Education Are Highlights of
National Grid: Delivering the Future of Heat